Approaches To Immunological Intervention In Schistosomiasis

$397,399ZIAFY2018AINIH

National Institute Of Allergy And Infectious Diseases

Investigators

Linked publications, trials & patents

Paper 28652398 Paper 27903651 Paper 27838188 Paper 27421703 Paper 27125685 Paper 27043413 Paper 26982353 Paper 26810038 Paper 26505816 Paper 25921340 Paper 25882242 Paper 25211233 Paper 25035950 Paper 24954262 Paper 24466060 Paper 24458645 Paper 24442439 Paper 24204274 Paper 23827958 Paper 23825948 Paper 23637937 Paper 23619691 Paper 23536877 Paper 23257921 Paper 23209401 Paper 23046809 Paper 22660926 Paper 22593615 Paper 22541242 Paper 22245779 Paper 21997792 Paper 21952807 Paper 21864478 Paper 21829367 Paper 21810604 Paper 21727191 Paper 21589896 Paper 21502330 Paper 21378263 Paper 21292997 Paper 21248152 Paper 21064130 Paper 20974983 Paper 20951137 Paper 20671265 Paper 20665377 Paper 20442785 Paper 20220096 Paper 20181883 Paper 19770272 Paper 19587021 Paper 19536189 Paper 19414799 Paper 19381262 Paper 19360123 Paper 19155511 Paper 19129758 Paper 18981114 Paper 18978793 Paper 18723022 Paper 18322219 Paper 17982031 Paper 17585010 Paper 17332879 Paper 17283209 Paper 16778988 Paper 16772607 Paper 16495517 Paper 16380294 Paper 16131912 Paper 15998470 Paper 15546394 Paper 15526002 Paper 15504820 Paper 15501755 Paper 15361239 Paper 15356151 Paper 15277569 Paper 14999686 Paper 14978122 Paper 14699044 Paper 14525773 Paper 14500760 Paper 14500663 Paper 12642601 Paper 12615888 Paper 12521263 Paper 12379664 Paper 11859129 Paper 11739522 Paper 11714822 Paper 11714756 Paper 11641263 Paper 11598048 Paper 11586433 Paper 11481612 Paper 11401959 Patent 7910105 Patent 7282206 Patent 6664227

Abstract

In schistosomiasis and other diseases associated with type-2 immunity, the pathology resulting from chronic infection or chronic allergen exposure is predominantly induced by the host immune response. The chronic type-2 immune response eventually triggers significant fibrosis, which is the primary cause of morbidity and mortality in many chronic infectious and inflammatory diseases. Our work is focused on elucidating the mechanisms of granulomatous inflammation, fibrosis, portal hypertension, and death following infection with S. mansoni and to devise novel strategies to slow or reverse the progression of liver fibrosis. Over the preceding 10 months, our work has focused on finishing up remaining projects as the Wynn lab was slated to close June 30, 2018. Two submitted papers are currently under revision.

View original record on NIH RePORTER →